Evidence map›Paper›PMID 39347942›Full record

Trial reportInternational journal of hematology2024

Silent inactivation of asparaginase in Japan: results of the prospective ALL-ASP19 trial.

Hidemi Shimonodan, Kimiyoshi Sakaguchi, Takashi Ishihara, Yasuhiro Okamoto, Takuro Nishikawa, Dai Keino, Reo Tanoshima, Souichi Suenobu

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hidemi Shimonodan *Department of Pediatrics, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan.
Kimiyoshi Sakaguchi *Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Takashi IshiharaDepartment of Pediatrics, Nara Medical University, Kashihara, Japan.
Yasuhiro OkamotoDepartment of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Takuro NishikawaDepartment of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Dai KeinoDivision of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Reo TanoshimaDepartment of Health Data Science, Graduate School of Data Science, Yokohama City University, Yokohama, Japan.
Souichi SuenobuDepartment of Pediatrics, Division of General Pediatrics and Emergency Medicine, Oita University, 1-1 Idaigaoka Hasama, Yufu, 879-5593, Japan. suenobu@oita-u.ac.jp.ORCID http://orcid.org/0000-0002-6266-1088

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Silent inactivation (SI) of L-asparaginase (ASP) is a phenomenon by which a neutralizing antibody for ASP (AAA) decreases ASP activity (ASA) in patients without a clinical allergy to ASP. Acute lymphoblastic leukemia (ALL) has a poor prognosis in patients with SI. Therefore, measurement of ASA levels, not AAA levels, is needed to identify patients with SI. We herein report the results of the prospective clinical trial ALL-ASP19, the first study in Japan to measure ASA and AAA to identify patients with SI. A total of 110 newly diagnosed ALL patients were enrolled, and ASA levels were measured three times during ALL treatment. Besides the 12 patients who discontinued the study, 32 were excluded due to inappropriate frequency and timing of ASA measurements and inappropriate ASP dosing. The remaining 66 patients were analyzed, and 3 patients with SI (4.5%) were identified. The incidence of SI is lower in Japan than in other countries. AAA was detected in all patients with SI, but four of the seven patients with AAA did not develop SI. Clinical characteristics did not significantly differ between patients with and without SI. Therefore, ASA levels must be measured to identify patients receiving insufficient ASP treatment.

Indexed as

AsparaginasePrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultAgedAntibodies, NeutralizingAntineoplastic AgentsChildChild, PreschoolFemaleHumansJapanMaleMiddle AgedProspective StudiesYoung AdultAntibodies, NeutralizingAntineoplastic AgentsAsparaginaseAcute lymphoblastic leukemiaAnti-asparaginase antibodyAsparaginase activitySilent inactivation

Identifiers

PMID39347942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.